| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations
|
Jutzi, Jonas Samuel
|
|
|
133 |
16 |
p. 1766-1777
|
artikel
|
| 2 |
Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion
|
Plesa, Adriana
|
|
|
133 |
16 |
p. 1789
|
artikel
|
| 3 |
Context-specific tumor suppression by PHF6
|
Trowbridge, Jennifer J.
|
|
|
133 |
16 |
p. 1698-1700
|
artikel
|
| 4 |
Disrupted filamin A/αIIbβ3 interaction induces macrothrombocytopenia by increasing RhoA activity
|
Donada, Alessandro
|
|
|
133 |
16 |
p. 1778-1788
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
133 |
16 |
p. i
|
artikel
|
| 6 |
αIIbβ3 changes gears in MKs and platelets
|
Sugimoto, Naoshi
|
|
|
133 |
16 |
p. 1700-1701
|
artikel
|
| 7 |
Nankanja R, Kiyaga C, Geisberg M, Serrao E, Balyegyusa S. Implementation of a sickle cell disease screening initiative in Uganda with HemoTypeSC™ [abstract]. Blood. 2018;132(suppl 1). Abstract LBA-3.
|
|
|
|
133 |
16 |
p. 1790
|
artikel
|
| 8 |
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
|
Forero-Torres, Andres
|
|
|
133 |
16 |
p. 1742-1752
|
artikel
|
| 9 |
Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease
|
Zhang, Lu
|
|
|
133 |
16 |
p. 1720-1728
|
artikel
|
| 10 |
PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia
|
McRae, Helen M.
|
|
|
133 |
16 |
p. 1729-1741
|
artikel
|
| 11 |
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
|
Hsi, Eric D.
|
|
|
133 |
16 |
p. 1762-1765
|
artikel
|
| 12 |
Storming the Castle with TCP
|
van Rhee, Frits
|
|
|
133 |
16 |
p. 1697-1698
|
artikel
|
| 13 |
Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL
|
Curran, Emily
|
|
|
133 |
16 |
p. 1715-1719
|
artikel
|
| 14 |
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
|
Willemze, Rein
|
|
|
133 |
16 |
p. 1703-1714
|
artikel
|
| 15 |
Viral, immunologic, and clinical features of primary effusion lymphoma
|
Lurain, Kathryn
|
|
|
133 |
16 |
p. 1753-1761
|
artikel
|
| 16 |
2018 WHO-EORTC classification update
|
|
|
|
133 |
16 |
p. 1791
|
artikel
|
Tijdschrift beschrijving